For 2022, it is estimated that the global CRO market stood at some 57 billion U.S. dollars. This statistic shows the market size of contract research organizations (CROs) globally in 2022 and a forecast for 2032.

This statistic shows the forecasted total addressable contract research organization (CRO) market worldwide in 2018, by function. It is estimated that the total addressable market in the function of discovery will reach 7.35 billion U.S. dollars in 2018.

[218+ Pages Report] The global Contract Research Organization CRO Services market size is expected to grow from USD 68.82 billion in 2023 to USD 134.65 billion by 2032, at a CAGR of 7.74% from 2024-2032

Snapshot img

Contract Research Organization Market Size 2025-2029

The contract research organization (CRO) market size is forecast to increase by USD 85.3 billion at a CAGR of 14.6% between 2024 and 2029.

The market is experiencing significant growth due to the expansion of the biopharmaceutical industry and the increasing number of clinical trials. The biopharmaceutical sector's growth is driven by the rising prevalence of chronic diseases, the ongoing research and development of new treatments, and the integration of telemedicine and gene therapy advancements. Additionally, CROs provide cost savings and efficiency to pharmaceutical and biotech companies by managing clinical trials and regulatory compliance. BioAgile Therapeutics, a leading company offers contract research organization (CRO) services such as comprehensive clinical research solutions, including medical writing, clinical data management, site management, and regulatory services tailored for pharmaceuticals and medical devices.

What will be the Size of the Contract Research Organization (CRO) Market during the forecast period?

Request Free Sample

The market encompasses a diverse range of services essential to pharmaceutical and biotechnology companies in their quest for new drug discoveries and regulatory approvals. Key areas of focus include oncology research, pharmaceutical development, clinical trial management, regulatory affairs, pharmacovigilance, drug discovery, clinical trial design, and drug safety. CROs also provide expertise in personalized medicine, clinical data management, data analysis, biostatistics, clinical operations, medical research, and healthcare consulting. Additionally, they offer services related to healthcare technology, immunotherapy, cell therapy, precision medicine, drug delivery, clinical trial recruitment, biomarker discovery, medical device development, and healthcare analytics. CROs play a pivotal role in various phases of pharmaceutical development, from early-stage research to post-market surveillance, enabling healthcare innovation and investment in the life sciences sector.

How is this Contract Research Organization (CRO) Industry segmented?

The contract research organization (CRO) industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Application

  Clinical research
  Early phase development
  Laboratory
  Regulatory consulting


End-user

  Pharmaceutical and biopharmaceutical companies
  Medical device companies
  Academic institutes


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    UK


  Asia
  Rest of World (ROW)

By Application Insights

The clinical research segment is estimated to witness significant growth during the forecast period. Contract Research Organizations (CROs) provide essential clinical research services, overseeing the strategic planning, execution, and oversight of clinical trials. Their expertise includes designing trial protocols, selecting investigative sites, and managing patient recruitment. CROs ensure regulatory compliance, implement rigorous monitoring and maintain data quality throughout the trial process. This accelerates drug development, enhancing efficiency and compliance. Research centers collaborate with CROs for tissue-based clinical research, funded by key players or governments, expanding their research and development capabilities. CROs offer services in various sectors, including pharmaceuticals, biotechnology, oncology drugs, drug development, clinical operations, oncology clinical trials, immunological disorders, regulatory affairs, biopharmaceuticals, analytical testing, respiratory disorders, healthcare, product approval, raw material testing, diabetes, target identification, data analytics, and medical devices.

Their role is crucial in the development of new treatments for cardiovascular diseases, genomic testing, cell gene therapy, and genomic testing devices. CROs also provide quality assurance, regulatory consulting, investments, mergers, productivity research services, patient population management, and clinical trial supplies.

Get a glance at the market report of share of various segments Request Free Sample

The Clinical research segment was valued at USD 31.00 billion in 2019 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 40% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market size of various regions, Request Free Sample

The market in North America holds a significant share due to the presence of numerous pha

In 2023, the leading contract research organizations worldwide included Laboratory Corporation of America Holdings, Thermo Fisher Scientific, and IQVIA. The first ranked company, Thermo Fisher Scientific, which acquired Pharmaceutical Product Development (PPD) in 2021, generated over 23 billion U.S. dollars in revenue through its clinical research business. Contract research organizations Contract research organizations (CROs) are companies that are contracted by larger pharmaceutical companies to manage select aspects of clinical trials. Today, CROs are essential for pharmaceutical research and development. Pharmaceutical companies are spending more money than ever on research and development, and there is no indication that spending will decrease in the future. Evidence suggests that CROs will become even more valuable. The clinical CRO market is expected to increase to over 100 billion U.S. dollars by the beginning of the next decade. Pharmaceutical research and development Globally, Roche and Johnson & Johnson will be the top pharmaceutical companies based on their projected research and development spending. There are regional differences in research and development among pharmaceutical companies. Of all pharmaceutical companies globally, those based in the U.S. develop the highest number of new chemical or biological entities.

Contract Research Organizations (CRO) Market size was valued at USD 7.1 Billion in 2024 and is projected to reach USD 16.8 Billion by 2031, growing at a CAGR of 11.74 % from 2024 to 2031.

Global Contract Research Organizations (CRO) Market Drivers

Emergence of Biopharmaceuticals and Startups: The rise of biopharmaceutical companies and startups has created new opportunities for the CRO market. These companies, often operating with limited resources and expertise, rely heavily on CROs for drug discovery, preclinical studies, and clinical trial management. The growing pipeline of biopharmaceutical products further fuels the demand for CRO services.

Technological Advancements: The adoption of technologies such as artificial intelligence (AI), big data analytics, and cloud computing is transforming the CRO landscape. These tools enhance the efficiency and accuracy of clinical trials, enabling faster data analysis and improved decision-making. CROs that leverage these technologies are better positioned to meet client demands and drive market growth.

The U.S. Contract Research Organization (CRO) Services Market size was valued at USD 32.99 USD Billion in 2023 and is projected to reach USD 70.68 USD Billion by 2032, exhibiting a CAGR of 11.5 % during the forecast period. The U.S. Contract Research Organization (CRO) market includes organizations offering issued contracts for research services to pharmaceutical, biotechnology, and medical device companies. These renderings cover broadly clinical trials, regulatory affairs, data management, biostatistics, and pharmacovigilance. CROs are fully utilized by pharmaceutical companies to enhance drug development procedures, curb costs, and shorten the drug market entry period. Ranges cover early-stage phase clinical trials and post-marketing surveillance. Key trends in the market comprise the introduction of CRO services which are specialized, growing virtual trials and decentralized clinical trials, and the use of AI and real-world evidence in clinical research is the fourth trend. US CRO services are a vital part of evolving and globalizing the pharmaceutical industry, which allows drug development endeavors to achieve success and operate efficiently. Key drivers for this market are: Rising Prevalence of Poultry Diseases is Anticipated to Drive the Market Growth. Potential restraints include: Limited Availability of Experienced Workforce is Expected to Restrict Market Growth. Notable trends are: Increasing Number of Hospitals and ASCs Identified as Significant Market Trend.

The global contract research organization (CRO) market size was worth around USD 58.48 billion in 2022 and is predicted to grow to around USD 123.65 billion by 2030

This statistic shows the market share of clinical contract research organizations (CROs) worldwide as of 2016, by company. As of that year, the market share of Quintiles was 13 percent and the market share of LabCorp was four percent amongst all clinical CROs worldwide.

Healthcare Contract Research Outsourcing Market size was valued at USD 43.22 Billion in 2024 and is projected to reach USD 75.66 Billion by 2031, growing at a CAGR of 7.25% during the forecast period 2024-2031.

Global Healthcare Contract Research Outsourcing Market Drivers

The market drivers for the Healthcare Contract Research Outsourcing Market can be influenced by various factors. These may include:

Increasing Research and Clinical Trial Involvement: There has been an increase in research and development activity in the biotechnology and pharmaceutical sectors, which has raised the need for clinical trial outsourcing. Healthcare CROs are essential to the success of these trials and the expansion of the market as a whole.

Time savings and cost effectiveness: Drug development can proceed more quickly and with lower operating expenses for pharmaceutical and biotech businesses that outsource their clinical research operations to CROs. CROs frequently have specialized infrastructure and knowledge, which boosts productivity and shortens turnaround times.

Global Clinical Trials Industry: The increasing number of clinical trials being done in different parts of the world has led to the demand for CROs with local knowledge who can manage a variety of trial populations and negotiate regulatory environments.

The intricacy of the drug development process: With developments in personalized medicine, genetics, and medical research, the process of developing new drugs has grown increasingly intricate. To take use of CROs’ specialized resources and skills, pharmaceutical corporations outsource different parts of clinical trials to them.

Strategic Emphasis on Fundamental Skills: Many biotech and pharmaceutical businesses would rather outsource their clinical research operations to specialized CROs and concentrate on their core skills, such marketing and drug discovery. They are able to distribute resources more skillfully as a result.

Snapshot img

Preclinical CRO Market Size 2025-2029

The preclinical CRO market size is forecast to increase by USD 2.73 billion at a CAGR of 8.1% between 2024 and 2029.

The market is experiencing significant growth due to the increasing prevalence of chronic diseases and the rising number of clinical trials. The trend towards outsourcing research activities to CROs is gaining momentum, as it allows players in industries such as pharmaceutical and biotech to reduce costs and improve efficiency.
However, intellectual property (IP) issues pose a challenge to the growth of the CRO industry. As the number of collaborations and partnerships increases, ensuring proper IP protection becomes crucial. As per the Centers for Disease Control and Prevention (CDC) 2022 statistics, around 60% of adult Americans have one chronic disease or more due to a sedentary lifestyle, unhealthy diet habits, and consumption of tobacco, which are likely to increase.

What will be the Size of the Preclinical CRO Market During the Forecast Period?

Request Free Sample

The preclinical Contract Research Organizations (CRO) market encompasses a significant segment of the global life sciences industry, specializing in large molecule preclinical studies for therapeutics and medical devices. These organizations play a pivotal role In the drug approval process, conducting preclinical trials to assess safety and efficacy. CROs utilize various models, including patient-derived organoids and immunodeficient mice, to simulate human physiology and disease states. Funding for preclinical research comes from various sources, including organizations, governments, and private investors.



Innovation In the market is driven by breakthroughs in biotechnology, such as the use of derived organoids and cryopreserved cells for diagnosis and prognosis. This has led to advancements in areas like neurology, oncology, infectious diseases, and metabolic disorders. The market is also witnessing a shift towards personalized healthcare, with a growing focus on drug metabolism and individual patient needs. The market caters to various therapeutic areas, including chronic diseases and malignancies, and is a critical link In the development of new therapeutics and medical devices.

How is this Preclinical CRO Industry segmented and which is the largest segment?

The preclinical CRO industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

End-user

  P and B companies
  Medical device companies
  Academic institutes


Service

  Toxicology testing
  Bioanalysis and DMPK studies
  Compound management
  Others


Geography

  North America

    Canada
    Mexico
    US


  Europe

    Germany
    UK
    France
    Italy


  Asia

    China
    India
    Japan


  Rest of World (ROW)

By End-user Insights

The P and B companies segment is estimated to witness significant growth during the forecast period.

Contract Research Organizations (CROs) have become indispensable partners for pharmaceutical and biopharmaceutical companies, enabling them to extend their capabilities without incurring additional overhead. Over the past two decades, the collaboration between these organizations has grown significantly due to several factors. The increasing demand for generic drugs and biologics, the capital-intensive nature of the industry, and the intricate manufacturing requirements have led many companies to outsource preclinical studies, including drug metabolism, toxicology testing, bioanalysis, and pharmacokinetic services. Preclinical trials involving large molecules, immunodeficient mice, and patient-derived organoids for personalized healthcare are crucial In the development of breakthrough drugs for chronic diseases such as neurology, oncology, cardiology, and infectious diseases.

CROs provide cost containment and regulatory compliance, adhering to guidelines for drug approval and regulatory policies. Services offered include noncore preclinical testing, bioequivalence studies, and in-house inventory management. Leading organizations have leveraged CROs to advance their drug candidates through clinical phases and bring innovative therapies to market.

Get a glance at the Preclinical CRO Industry report of share of various segments Request Free Sample

The P and B companies segment was valued at USD 2.74 billion in 2019 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 44% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

P

This dataset provides a structured and machine-readable register of all companies recorded by the Companies Registration Office (CRO) in Ireland. It includes a daily snapshot of company records, covering both currently registered companies and historical records of dissolved or closed entities. The dataset aligns with the European Union’s Open Data Directive (Directive (EU) 2019/1024) and the Implementing Regulation (EU) 2023/138, which designates company and company ownership data as a high-value dataset. Updated daily, it ensures timely access to corporate information and is available for bulk download and API access under the Creative Commons Attribution 4.0 (CC BY 4.0) licence, allowing unrestricted reuse with appropriate attribution. By increasing transparency, accountability, and economic innovation, this dataset supports public sector initiatives, research, and digital services development.

The Preclinical Contract Research Organization (CRO) market plays a pivotal role in the pharmaceutical and biotechnology industries by offering essential services in the early stages of drug development. Preclinical CROs provide invaluable support in conducting experiments and studies needed to assess the safety and

The Clinical Trials Dashboard market is experiencing robust growth, driven by the increasing need for efficient data management and real-time monitoring in clinical trials. The market, valued at approximately $2.5 billion in 2025, is projected to exhibit a Compound Annual Growth Rate (CAGR) of 15% from 2025 to 2033. This expansion is fueled by several key factors. Firstly, the rising complexity of clinical trials, involving larger patient populations and more diverse data sets, necessitates sophisticated dashboards for streamlined oversight. Secondly, regulatory pressures demanding enhanced data transparency and accountability are pushing adoption. Thirdly, technological advancements, including cloud computing and AI-powered analytics, are enabling the development of more sophisticated and user-friendly dashboards. The integrated system segment currently holds the largest market share due to its comprehensive functionality, but the independent system segment is experiencing significant growth driven by flexibility and cost-effectiveness for smaller organizations. Hospitals and CROs are major adopters, although Pharma & Biotech organizations are increasingly investing in these solutions. Geographical analysis reveals strong market presence across North America and Europe, driven by established healthcare infrastructure and high research and development spending. However, the Asia Pacific region is poised for rapid growth due to increasing clinical trial activity and expanding healthcare IT investments. The market's growth trajectory is, however, susceptible to factors like high implementation costs, data security concerns, and the need for skilled personnel to manage and interpret the data generated by these sophisticated systems. This necessitates focused investment in training and robust security measures to fully realize the market's potential. Further, successful integration with legacy systems remains crucial for wide-scale adoption within existing clinical trial workflows.

CRO Services Market size is valued at USD 67.16 Billion in 2024 and is anticipated to reach USD 160.9 Billion by 2031, growing at a CAGR of 11.54% from 2024 to 2031

Global Contract Research Organizations Services Market Drivers

Growing Need for Novel Drugs: The pharmaceutical business is being driven to provide novel and inventive therapies due to the increasing prevalence of chronic illnesses including diabetes, cancer, and cardiovascular disorders. Clinical trials, a primary service provided by CROs, become more necessary as a result.

Patent Expirations: When a drug’s patent expires, generic substitutes and the creation of new drugs are given a chance. This increases competitiveness and calls for quicker drug development schedules, which CROs can handle with ease.

Globalization of Clinical studies: Because of things like cheaper prices and bigger patient pools, pharmaceutical corporations are performing more and more clinical studies in developing nations. CROs with a global reach and regulatory landscape navigation knowledge are attractive partners.

This statistic shows the total contract research organization (CRO) market worldwide from 2015 to 2024. It was estimated that in 2023, the total market of CROs will be around 88 billion U.S. dollars worldwide.

The market size of the Healthcare Contract Research Organization Cro Market is categorized based on Application (Project management/clinical supply management, Data management, Regulatory/medical affairs, Medical writing, Clinical monitoring, Quality management/assurance, Bio-statistics, Investigator payments, Laboratory patient) and Product (Drug Discovery, Pre-Clinical) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

This report provides insights into the market size and forecasts the value of the market, expressed in USD million, across these defined segments.

The size and share of the market is categorized based on Application (Project management/clinical supply management, Data management, Regulatory/medical affairs, Medical writing, Clinical monitoring, Quality management/assurance, Bio-statistics, Investigator payments, Laboratory patient, Site recruitment technology) and Product (Drug Discovery, Pre-Clinical, Clinical) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

The global CRO services market size was valued at USD XXX million in 2025 and is projected to grow at a CAGR of XX% during the forecast period 2025-2033. The rising demand for outsourced clinical research services, particularly in the pharmaceutical and biotechnology industries, is a key driver of market growth. CROs provide specialized expertise, operational efficiency, and access to global resources, enabling pharmaceutical and biotechnology companies to streamline their drug development processes and reduce costs. Key trends shaping the market include the increasing adoption of technology in clinical trials, such as artificial intelligence and machine learning, which enhance data analysis and improve trial efficiency. Additionally, globalization of clinical trials is driving demand for CROs with international capabilities and expertise in managing diverse regulatory requirements. However, challenges such as data security concerns, regulatory complexities, and the need for skilled professionals may restrain market growth. The market is highly competitive, with established players such as PPD, ICON, Algorithme, PRA, Syneos Health, Parexel, IQVIA, and Charles River - WIL Research dominating the industry.

This statistic shows the market share of preclinical contract research organizations (CROs) worldwide as of 2016. As of that year, the market share of Charles River was 11 percent and the market share of LabCorp was 14 percent amongst all preclinical CROs worldwide.